1-155238141-A-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong
The NM_000157.4(GBA1):c.754T>A(p.Phe252Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000204 in 1,614,028 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 30)
Exomes 𝑓: 0.000022 ( 0 hom. )
Consequence
GBA1
NM_000157.4 missense
NM_000157.4 missense
Scores
9
5
5
Clinical Significance
Conservation
PhyloP100: 6.35
Genes affected
GBA1 (HGNC:4177): (glucosylceramidase beta 1) This gene encodes a lysosomal membrane protein that cleaves the beta-glucosidic linkage of glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene cause Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. A related pseudogene is approximately 12 kb downstream of this gene on chromosome 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
In a helix (size 18) in uniprot entity GBA1_HUMAN there are 5 pathogenic changes around while only 0 benign (100%) in NM_000157.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.868
PP5
Variant 1-155238141-A-T is Pathogenic according to our data. Variant chr1-155238141-A-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 4301.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBA1 | NM_000157.4 | c.754T>A | p.Phe252Ile | missense_variant | 6/11 | ENST00000368373.8 | NP_000148.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBA1 | ENST00000368373.8 | c.754T>A | p.Phe252Ile | missense_variant | 6/11 | 1 | NM_000157.4 | ENSP00000357357.3 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
1
AN:
152156
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000437 AC: 11AN: 251488Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135916
GnomAD3 exomes
AF:
AC:
11
AN:
251488
Hom.:
AF XY:
AC XY:
5
AN XY:
135916
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000219 AC: 32AN: 1461872Hom.: 0 Cov.: 32 AF XY: 0.0000261 AC XY: 19AN XY: 727234
GnomAD4 exome
AF:
AC:
32
AN:
1461872
Hom.:
Cov.:
32
AF XY:
AC XY:
19
AN XY:
727234
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 74344
GnomAD4 genome
AF:
AC:
1
AN:
152156
Hom.:
Cov.:
30
AF XY:
AC XY:
0
AN XY:
74344
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
2
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:12Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Gaucher disease Pathogenic:3Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 18, 2020 | Variant summary: GBA c.754T>A (p.Phe252Ile) results in a non-conservative amino acid change located in the Glycosyl hudrolase family 30, TIM-barrel domain (IPR033453) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.4e-05 in 251488 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in GBA causing Gaucher Disease (4.4e-05 vs 0.005), allowing no conclusion about variant significance. c.754T>A has been reported in the literature in multiple individuals from diverse ethnic backgrounds affected with Gaucher Disease, example, Japanese (Kawame_1991), English (He_1992), Italian (Filocamo_1992), Thai (Suwannarat_2007), and Indian (Sheth_2019), in addition to patients affected with Parkinson's disease (example, Trinh_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity in transient expression of Glucocerebrosidase activity in transfected COS-1 cells (example, Kawame_1991). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic using overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Phe2252Ile variant in GBA has been reported in at least 17 individuals with Gaucher disease and has been identified in 0.010% (2/19954) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs381737). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (VariationID: 4301) as pathogenic by EGL Genetic Diagnostics and OMIM. In vitro functional studies provide some evidence that the p.Phe252Ile variant may impact protein function (PMID: 15276648). However, these types of assays may not accurately represent biological function. Computational prediction tools suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The Phe at position 252 is highly conserved in mammals and evolutionary distant species, but 1 mammal (Chimp) carries an Ile, raising the possibility that this change at this position may be tolerated. The presence of this variant in 4 affected homozygotes and in combination with reported pathogenic variants in 8 individuals with Gaucher disease increases the likelihood that the p.Phe252Ile variant is pathogenic (VariationID: 4296, 4288, 4327, 4328; PMID: 17689991, 20729108, 15954102, 30949558, 30764785, 29685539). The phenotype of individuals homozygous and compound heterozygous for this variant is highly specific for Gaucher disease based on significantly reduced levels of beta-glucosidase in patient leukocytes consistent with disease (PMID: 17689991, 30764785, 15954102). In summary, this variant meets criteria to be classified as pathogenic for Gaucher disease in an autosomal recessive manner based on the presence of the variant in combination with other pathogenic variants, in vitro functional studies, and the phenotype of individuals with the variant being highly specific for Gaucher disease. ACMG/AMP Criteria applied: PM3_very-strong, PS3_moderate, PM2_supporting, PP4 (Richards 2015). - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | May 06, 2017 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 03, 2021 | Published functional studies demonstrate that this variant results in deficient beta-glucocerebrosidase activity (Kawame et al., 1991; Kim et al., 2020); Also described in past literature as p.F213I using alternate nomenclature; This variant is associated with the following publications: (PMID: 32677286, 33176831, 27802905, 15954102, 15276648, 23430543, 20301446, 30764785, 30949558, 19830760, 31637888, 30537300, 12204005, 25435509, 25875285, 29699937, 14984463, 16720474, 17689991, 1840477, 1301953, 29685539, 29140481, 20729108) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 16, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 22, 2023 | This sequence change replaces phenylalanine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 252 of the GBA protein (p.Phe252Ile). This variant is present in population databases (rs381737, gnomAD 0.01%). This missense change has been observed in individual(s) with Gaucher disease and/or Parkinson's disease (PMID: 1301953, 12204005, 17689991, 29140481). This variant is also known as p.Phe213Ile. ClinVar contains an entry for this variant (Variation ID: 4301). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GBA protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects GBA function (PMID: 1840477). This variant disrupts the p.Phe252 amino acid residue in GBA. Other variant(s) that disrupt this residue have been observed in individuals with GBA-related conditions (PMID: 23430543), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Gaucher disease type I Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1992 | - - |
not specified Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 19, 2018 | The p.F252I variant (also known as c.754T>A, p.F213I, and c.3548T>A), located in coding exon 6 of the GBA gene, results from a T to A substitution at nucleotide position 754. The phenylalanine at codon 252 is replaced by isoleucine, an amino acid with highly similar properties. This alteration has been detected in individuals with confirmed diagnoses of Gaucher disease, in both homozygous and compound heterozygous states (Suwannarat P et al. Blood Cells Mol. Dis. Aug;39:348-52; Ortiz-Cabrera NV et al. Mol Genet Metab Rep, 2016 Dec;9:79-85; Santamaria R et al. Hum. Mutat., 2008 Jun;29:E58-67; Tang NL et al. Hum. Mutat., 2005 Jul;26:59-60; Kawame H et al. Am. J. Hum. Genet., 1991 Dec;49:1378-80; Latham TE et al. DNA Cell Biol.;10:15-21). In addition, in one study authors showed that, when this alteration was transfected into COS-1 cells, the glucosidase activity failed to increase as efficiently as normal cDNA (Kawame H et al. Am. J. Hum. Genet., 1991 Dec;49:1378-80). Of note, this alteration has also been detected in GBA pseudogene. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Gaucher disease type II;C0268251:Gaucher disease type III;C0752347:Lewy body dementia;C1842704:Gaucher disease perinatal lethal;C1856476:Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome;C1961835:Gaucher disease type I;C3160718:Parkinson disease, late-onset Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 29, 2021 | - - |
Gaucher disease type II Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1992 | - - |
Gaucher disease type III Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1992 | - - |
Lewy body dementia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Dec 19, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;T;T;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;T
Sift4G
Benign
T;T;T;T
Polyphen
B;B;.;.
Vest4
MVP
MPC
1.4
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at